OpenAI Foundation Appoints Dan Wattendorf to Lead Bio-Resilience
OpenAI Foundation Appoints Dan Wattendorf to Lead Bio-Resilience
On 31 July, OpenAI cofounder Wojciech Zaremba announced that Dan Wattendorf will lead Bio-Resilience at the OpenAI Foundation. Wattendorf previously launched biomedical programs at DARPA and later led the development of technologies for global health at the Gates Foundation.
“AI capabilities in biology bring exceptional benefits and serious risks. We need institutions and technologies that will prepare the world for them,” Zaremba wrote.
The Foundation's March plan lists curing diseases and resilience to AI risks among four areas to which it intends to commit at least $1 billion. In its section on AI resilience, the Foundation specifically identifies biosecurity as a priority, including outbreak detection, prevention, and containment of threats that AI could amplify.
Wattendorf comes to this role from programs focused on moving biological technologies into practical use. At DARPA, he worked on diagnostics, synthetic cell biology, RNA vaccines, and antibody discovery, according to his biography. At the Gates Foundation, his team developed, tested, and prepared new global health technologies for deployment.
The DARPA programs ADEPT and P3 show what this work involves. ADEPT delivered genetic instructions into cells instead of a finished antigen, the substance that triggers an immune response. The cells produced the protein and initiated that response. P3 identified, tested, and manufactured antibody treatments against emerging infections. Here, diagnostics, response development, and manufacturing form a single chain.
The OpenAI Foundation has placed Bio-Resilience under the leadership of someone who has worked across this chain. The appointment connects the Foundation's plans in biology with experience in moving technology from a laboratory concept through diagnostics, testing, and manufacturing. In the same March plan, the Foundation also committed to using AI for Alzheimer's disease research, open medical data, and diseases with high mortality rates.